KB-0742 by Kronos Bio for Ewing Sarcoma: Likelihood of Approval
KB-0742 is under clinical development by Kronos Bio and currently in Phase II for Ewing Sarcoma.
Source: pharmaceutical-technology.com
Page 7 - Kronos Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kronos Bio Today - Breaking & Trending Today
Kronos Bio Presents Positive Preliminary Data from Phase 1
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed...
Source: globenewswire.com
Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 ...
Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors
Source: eagletribune.com
Kronos Bio : Presentation -October 13, 2023 at 05:03 pm EDT
Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC October 13, 2023 ...
Source: marketscreener.com
Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13
Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of HopeSAN MATEO, Calif., and...
Source: marketscreener.com